Inventor
MUELLER PHILLIP
DE31 patents
⚠️ This page may combine multiple inventors who share the name “MUELLER PHILLIP”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMATICS BIOTECHNOLOGIES GMBH
28 patentsUS10449238B2Oct 22, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH18 citations98
US11826409B2Nov 28, 2023
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH6 citations94
US11065315B2Jul 20, 2021
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations94
US11058754B2Jul 13, 2021
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10799569B2Oct 13, 2020
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10532091B1Jan 14, 2020
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10478480B2Nov 19, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10376568B2Aug 13, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH14 citations94
US10155032B2Dec 18, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations93
US9993539B2Jun 12, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH13 citations93
US10064926B2Sep 4, 2018
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH12 citations90
US11786584B2Oct 17, 2023
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH4 citations86
US12180259B2Dec 31, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12144852B2Nov 19, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12102670B2Oct 1, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12097249B2Sep 24, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US12076381B2Sep 3, 2024
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations73
US11786583B2Oct 17, 2023
Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH1 citations73
US11679147B2Jun 20, 2023
Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
IMMATICS BIOTECHNOLOGIES GMBH2 citations73
US11672848B2Jun 13, 2023
Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
IMMATICS BIOTECHNOLOGIES GMBH2 citations73
US11576956B2Feb 14, 2023
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH2 citations73
US12121572B2Oct 22, 2024
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US12097248B2Sep 24, 2024
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US12076380B2Sep 3, 2024
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US12070491B2Aug 27, 2024
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US11779638B2Oct 10, 2023
Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US11559573B2Jan 24, 2023
Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
US11406693B2Aug 9, 2022
Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IMMATICS BIOTECHNOLOGIES GMBH0 citations62
immatics biotechnology GmbH
2 patentsUS10500259B2Dec 10, 2019
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
immatics biotechnology GmbH17 citations96
US9908920B2Mar 6, 2018
Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
immatics biotechnology GmbH15 citations95